Streetbeat News

Analyst Ratings

AXSM

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a price target of $108.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 1:21 pm

ARCT

Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Arcturus Therapeutics (NASDAQ:ARCT) and maintained a $54 price target.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 1:20 pm

ANNX

Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Annexon (NASDAQ:ANNX) and maintained a $13 price target.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 1:19 pm

OKTA

Canaccord Genuity analyst Michael Walkley maintains a 'Hold' rating on Okta (NASDAQ:OKTA) and lowers the price target from $85 to $75.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 1:19 pm

DFLI

Canaccord Genuity analyst George Gianarikas has maintained a 'Buy' rating on Dragonfly Energy Hldgs (NASDAQ:DFLI) but lowered the price target from $9 to $4.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 1:18 pm

ACAD

Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and maintained a $42 price target.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 1:17 pm

CRWD

Canaccord Genuity analyst Michael Walkley maintains a 'Buy' rating on CrowdStrike Holdings (NASDAQ:CRWD) and raises the price target from $175 to $185.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 1:16 pm

CMPS

Canaccord Genuity analyst Sumant Kulkarni maintains a 'Buy' rating on Compass Pathways (NASDAQ:CMPS) but lowers the price target from $60 to $50.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 1:15 pm

WEX

JP Morgan analyst Tien-Tsin Huang has maintained a Neutral rating on WEX (NYSE:WEX) and raised the price target from $218 to $233.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 1:09 pm

V

JP Morgan analyst Tien-Tsin Huang maintains an Overweight rating on Visa and raises the price target from $265 to $296.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 1:08 pm